POAI
Closed
Predictive Oncology Inc
0.841
+0.011 (+1.33%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.83
Day's Range: 0.815 - 0.87
Send
sign up or login to leave a comment!
When Written:
0.2703
Predictive Oncology Inc. is a precision medicine company that specializes in the development of personalized cancer therapies and diagnostics. The company's primary focus is on the use of artificial intelligence (AI) and predictive modeling to identify potential treatment options for individual cancer patients.
Predictive Oncology's AI platform, Helomics, uses data from patient tumors to create individualized models that can predict the response of cancer cells to different treatments. The company also offers a range of diagnostic tests, including its proprietary ChemoFx assay, which can help physicians determine the best chemotherapy options for their patients.
In addition to its precision medicine offerings, Predictive Oncology also provides contract research services to pharmaceutical and biotech companies. The company's research services include drug discovery, preclinical testing, and clinical trial support.
Predictive Oncology is headquartered in Minneapolis, Minnesota, and has additional offices in Pittsburgh, Pennsylvania, and Nashville, Tennessee. The company was founded in 2002 and went public in 2019.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Predictive Oncology's AI platform, Helomics, uses data from patient tumors to create individualized models that can predict the response of cancer cells to different treatments. The company also offers a range of diagnostic tests, including its proprietary ChemoFx assay, which can help physicians determine the best chemotherapy options for their patients.
In addition to its precision medicine offerings, Predictive Oncology also provides contract research services to pharmaceutical and biotech companies. The company's research services include drug discovery, preclinical testing, and clinical trial support.
Predictive Oncology is headquartered in Minneapolis, Minnesota, and has additional offices in Pittsburgh, Pennsylvania, and Nashville, Tennessee. The company was founded in 2002 and went public in 2019.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








